https://ocubrief.com/en/brief/nct03092492OcuBriefen2026-09-20T09:58:57.336ZAMD Ryan Initiative Study (ARIS)https://ocubrief.com/de/brief/nct03092492OcuBriefde2026-09-20T09:58:57.336ZAMD-Ryan-Initiative-Studie (ARIS)https://ocubrief.com/it/brief/nct03092492OcuBriefit2026-09-20T09:58:57.336ZStudio dell'iniziativa Ryan su AMD (ARIS)https://ocubrief.com/en/brief/nct07705555OcuBriefen2026-09-20T09:58:57.336ZA Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)https://ocubrief.com/de/brief/nct07705555OcuBriefde2026-09-20T09:58:57.336ZEine klinische Studie von MK-8748 im Vergleich zu Aflibercept bei Teilnehmern mit diabetischem Makulaödem (MK-8748-004)https://ocubrief.com/it/brief/nct07705555OcuBriefit2026-09-20T09:58:57.336ZStudio clinico di MK-8748 in confronto ad Aflibercept in partecipanti con edema maculare diabetico (MK-8748-004)https://ocubrief.com/en/brief/nct07567833OcuBriefen2026-09-20T09:58:57.336ZLongitudinal Study of Retinal Function in Eyes Treated for Diabetic Macular Edema With Anti-VEGF Agentshttps://ocubrief.com/de/brief/nct07567833OcuBriefde2026-09-20T09:58:57.336ZLängsschnittstudie der retinalen Funktion in Augen, die mit Anti-VEGF-Agenzien für diabetisches Makulaödem behandelt wurdenhttps://ocubrief.com/it/brief/nct07567833OcuBriefit2026-09-20T09:58:57.336ZStudio longitudinale della funzione retinica in occhi trattati con agenti anti-VEGF per edema maculare diabeticohttps://ocubrief.com/en/brief/nct06790784OcuBriefen2026-09-20T09:58:57.336ZFaricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDRhttps://ocubrief.com/de/brief/nct06790784OcuBriefde2026-09-20T09:58:57.336ZFaricimab + PRP vs. Vitrektomie + Endolaser zur Behandlung von PDRhttps://ocubrief.com/it/brief/nct06790784OcuBriefit2026-09-20T09:58:57.336ZFaricimab + PRP vs. vitrectomia + endolaser per il trattamento di PDRhttps://ocubrief.com/en/brief/nct06541704OcuBriefen2026-09-20T09:58:57.336ZA Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophyhttps://ocubrief.com/de/brief/nct06541704OcuBriefde2026-09-20T09:58:57.336ZEine Studie zur Untersuchung von subkutan verabreichtem Pozelimab in Kombination mit Cemdisiran oder Cemdisiran allein bei erwachsenen Teilnehmern mit geografischer Atrophiehttps://ocubrief.com/it/brief/nct06541704OcuBriefit2026-09-20T09:58:57.336ZUno studio per indagare Pozelimab somministrato sottocute in combinazione con Cemdisiran o solo Cemdisiran in partecipanti adulti con atrofia geograficahttps://ocubrief.com/en/brief/nct07440225OcuBriefen2026-09-20T09:58:57.336ZA Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)https://ocubrief.com/de/brief/nct07440225OcuBriefde2026-09-20T09:58:57.336ZEine klinische Studie von EYE201/MK-8748 bei Menschen mit Makuladegeneration (MK-8748-002)https://ocubrief.com/it/brief/nct07440225OcuBriefit2026-09-20T09:58:57.336ZUno studio clinico di EYE201/MK-8748 in persone con degenerazione maculare (MK-8748-002)https://ocubrief.com/en/brief/nct07215234OcuBriefen2026-09-20T09:58:57.336ZA Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degenerationhttps://ocubrief.com/de/brief/nct07215234OcuBriefde2026-09-20T09:58:57.336ZEine Studie zur Sicherheit und Wirksamkeit einer einmaligen intravitrealen Injektion von SAR446597 bei Teilnehmern mit geografischer Atrophie sekundär zu altersbedingter Makuladegenerationhttps://ocubrief.com/it/brief/nct07215234OcuBriefit2026-09-20T09:58:57.336ZUno studio sulla sicurezza e sull'efficacia di un'iniezione intravitreale unica di SAR446597 in partecipanti con atrofia geografica secondaria a degenerazione maculare legata all'etàhttps://ocubrief.com/en/brief/nct06491914OcuBriefen2026-09-20T09:58:57.336ZA Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)https://ocubrief.com/de/brief/nct06491914OcuBriefde2026-09-20T09:58:57.336ZPhase-3b-Studie mit einem Arm zur Untersuchung von Aflibercept 8 mg, verabreicht alle 4 Wochen, bei erwachsenen Teilnehmern mit neovaskulärer altersbedingter Makuladegeneration (nAMD) oder diabetischem Makulaödem (DME)https://ocubrief.com/it/brief/nct06491914OcuBriefit2026-09-20T09:58:57.336ZStudio di fase 3b, a braccio singolo, di aflibercept 8 mg somministrato ogni 4 settimane in partecipanti adulti con degenerazione maculare neovascolare legata all'età (nAMD) o edema maculare diabetico (DME)https://ocubrief.com/en/brief/nct06370039OcuBriefen2026-09-20T09:58:57.336ZStudy of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Diseasehttps://ocubrief.com/de/brief/nct06370039OcuBriefde2026-09-20T09:58:57.336ZStudie zur INV-102-Augentropfenlösung bei Erwachsenen mit mittelschwerer bis schwerer Erkrankung des trockenen Augeshttps://ocubrief.com/it/brief/nct06370039OcuBriefit2026-09-20T09:58:57.336ZStudio della soluzione oftalmica INV-102 in adulti con malattia dell’occhio secco da moderata a gravehttps://ocubrief.com/en/brief/nct05586152OcuBriefen2026-09-20T09:58:57.336ZStudy of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Diseasehttps://ocubrief.com/de/brief/nct05586152OcuBriefde2026-09-20T09:58:57.336ZStudie zur INV-102-Augentropfenlösung bei Erwachsenen mit symptomatischer, mittelschwerer Erkrankung des trockenen Augeshttps://ocubrief.com/it/brief/nct05586152OcuBriefit2026-09-20T09:58:57.336ZStudio della soluzione oftalmica INV-102 in adulti con malattia dell’occhio secco sintomatica moderatahttps://ocubrief.com/en/brief/nct07246915OcuBriefen2026-09-20T09:58:57.336ZLong-term Safety & Performance of REVISYON SDS100 in Mild to Moderate Cataract: Extension Study (EB-CE-02)https://ocubrief.com/de/brief/nct07246915OcuBriefde2026-09-20T09:58:57.336ZLangzeit-Sicherheit und Leistung von REVISYON SDS100 bei leichter bis mäßiger Katarakt: Verlängerungsstudie (EB-CE-02)https://ocubrief.com/it/brief/nct07246915OcuBriefit2026-09-20T09:58:57.336ZStudio di sicurezza e prestazioni a lungo termine di REVISYON SDS100 nella cataratta lieve o moderata: studio di estensione (EB-CE-02)https://ocubrief.com/en/brief/nct07828821OcuBriefen2026-09-20T09:58:57.336ZScreening for Diabetic RETINopathy Using a Non-mydriatic Retinograph Funduscope in Occupational MEDicinehttps://ocubrief.com/de/brief/nct07828821OcuBriefde2026-09-20T09:58:57.336ZScreening auf diabetische Retinopathie unter Verwendung eines nicht-mydriatischen Retinographen-Fundusskops in der Arbeitsmedizinhttps://ocubrief.com/it/brief/nct07828821OcuBriefit2026-09-20T09:58:57.336ZScreening per retinopatia diabetica utilizzando un retinografo a fondo oculare non midriatico in medicina del lavorohttps://ocubrief.com/en/brief/nct07766473OcuBriefen2026-09-20T09:58:57.336ZFirst in Human Study of BETA-TT8 in wetAge-related Macular Degeneration (wetAMD)https://ocubrief.com/de/brief/nct07766473OcuBriefde2026-09-20T09:58:57.336ZErste Studie am Menschen mit BETA-TT8 bei feuchter altersbedingter Makuladegeneration (wetAMD)https://ocubrief.com/it/brief/nct07766473OcuBriefit2026-09-20T09:58:57.336ZPrimo studio nell’uomo di BETA-TT8 nella degenerazione maculare neovascolare legata all’età (wetAMD)https://ocubrief.com/en/brief/nct07005323OcuBriefen2026-09-20T09:58:57.336ZProgression Suppression and Retinal Regression in VEGF-resistant AMDhttps://ocubrief.com/de/brief/nct07005323OcuBriefde2026-09-20T09:58:57.336ZProgressionshemmung und retinale Regression bei VEGF-resistenter AMDhttps://ocubrief.com/it/brief/nct07005323OcuBriefit2026-09-20T09:58:57.336ZSoppressione della progressione e regressione retinica nell’AMD resistente al VEGFhttps://ocubrief.com/en/brief/nct00594672OcuBriefen2026-09-20T09:58:57.336ZAge-Related Eye Disease Study (AREDS) Follow-Uphttps://ocubrief.com/de/brief/nct00594672OcuBriefde2026-09-20T09:58:57.336ZStudie zur altersbedingten Augenkrankheit (AREDS) - Nachbeobachtunghttps://ocubrief.com/it/brief/nct00594672OcuBriefit2026-09-20T09:58:57.336ZStudio sulla malattia oculare legata all'età (AREDS) - follow-uphttps://ocubrief.com/en/brief/nct05955846OcuBriefen2026-09-20T09:58:57.336ZEvaluation of Safety and Effectiveness of an IOL With a Virtual Aperture Optichttps://ocubrief.com/de/brief/nct05955846OcuBriefde2026-09-20T09:58:57.336ZBewertung der Sicherheit und Wirksamkeit einer IOL mit virtueller Blendeoptikhttps://ocubrief.com/it/brief/nct05955846OcuBriefit2026-09-20T09:58:57.336ZValutazione della sicurezza e dell’efficacia di una IOL con ottica ad apertura virtualehttps://ocubrief.com/en/brief/nct07419334OcuBriefen2026-09-20T09:58:57.336ZStudy of ALK-001 on the Progression of Stargardt Diseasehttps://ocubrief.com/de/brief/nct07419334OcuBriefde2026-09-20T09:58:57.336ZStudie zu ALK-001 hinsichtlich des Fortschreitens der Stargardt-Krankheithttps://ocubrief.com/it/brief/nct07419334OcuBriefit2026-09-20T09:58:57.336ZStudio di ALK-001 sulla progressione della malattia di Stargardthttps://ocubrief.com/en/brief/nct07826286OcuBriefen2026-09-20T09:58:57.336ZChanges in Intraocular Pressure After Intravitreal Injectionhttps://ocubrief.com/de/brief/nct07826286OcuBriefde2026-09-20T09:58:57.336ZVeränderungen des Augeninnendrucks nach intravitrealer Injektionhttps://ocubrief.com/it/brief/nct07826286OcuBriefit2026-09-20T09:58:57.336ZCambiamenti della pressione intraoculare dopo iniezione intravitrealehttps://ocubrief.com/en/brief/nct07075718OcuBriefen2026-09-20T09:58:57.336ZPhase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implanthttps://ocubrief.com/de/brief/nct07075718OcuBriefde2026-09-20T09:58:57.336ZPhase-2-Studie zur Bewertung der Sicherheit und Wirksamkeit des intrakameralen Travoprost-Implantats der zweiten Generationhttps://ocubrief.com/it/brief/nct07075718OcuBriefit2026-09-20T09:58:57.336ZStudio di fase 2 per valutare la sicurezza e l'efficacia dell'impianto intracamerale di seconda generazione di travoprosthttps://ocubrief.com/en/brief/nct06373731OcuBriefen2026-09-20T09:58:57.336ZReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)https://ocubrief.com/de/brief/nct06373731OcuBriefde2026-09-20T09:58:57.336ZReNEW: Phase-3-Studie zur Wirksamkeit, Sicherheit und Pharmakokinetik von subkutanen Injektionen von Elamipretid bei Patienten mit trockener altersbedingter Makuladegeneration (Dry AMD)https://ocubrief.com/it/brief/nct06373731OcuBriefit2026-09-20T09:58:57.336ZReNEW: studio di fase 3 sull'efficacia, sicurezza e farmacocinetica di iniezioni sottocutanee di elamipretide in soggetti con degenerazione maculare secca legata all'età (dry AMD)https://ocubrief.com/en/brief/nct07592273OcuBriefen2026-09-20T09:58:57.336ZSurabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edemahttps://ocubrief.com/de/brief/nct07592273OcuBriefde2026-09-20T09:58:57.336ZSuprachoroidale Verabreichung von Surabgene Lomparvovec bei Erwachsenen mit diabetischer Retinopathie ohne zentrumsbeteiligtes diabetisches Makulaödemhttps://ocubrief.com/it/brief/nct07592273OcuBriefit2026-09-20T09:58:57.336ZSomministrazione sovracoroideale di surabgene lomparvovec in adulti con retinopatia diabetica senza edema maculare diabetico con coinvolgimento del centrohttps://ocubrief.com/en/brief/nct02246829OcuBriefen2026-09-20T09:58:57.336ZAssessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®)STARThttps://ocubrief.com/de/brief/nct02246829OcuBriefde2026-09-20T09:58:57.336ZBewertung früher Veränderungen im SD-OCT nach Beginn einer Behandlung mit intravitrealem Aflibercept (EYLEA®) - STARThttps://ocubrief.com/it/brief/nct02246829OcuBriefit2026-09-20T09:58:57.336ZValutazione dei cambiamenti precoci nella SD-OCT dopo l'inizio di un trattamento con aflibercept intravitreale (EYLEA®) - STARThttps://ocubrief.com/en/brief/nct07825337OcuBriefen2026-09-20T09:58:57.336ZPilot Study: Feasibility and Usability of a Head-Mounted Spatial Computing Device for Intraoperative Visualization During Intraocular Surgeryhttps://ocubrief.com/de/brief/nct07825337OcuBriefde2026-09-20T09:58:57.336ZPilotstudie: Machbarkeit und Benutzerfreundlichkeit eines head-mounted Spatial Computing-Geräts für die intraoperative Visualisierung während der intraokularen Chirurgiehttps://ocubrief.com/it/brief/nct07825337OcuBriefit2026-09-20T09:58:57.336ZStudio pilota: fattibilità e usabilità di un dispositivo di calcolo spaziale montato sulla testa per la visualizzazione intraoperatoria durante la chirurgia intraocularehttps://ocubrief.com/en/brief/nct07614776OcuBriefen2026-09-20T09:58:57.336ZA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degenerationhttps://ocubrief.com/de/brief/nct07614776OcuBriefde2026-09-20T09:58:57.336ZStudie zur Bewertung der Wirksamkeit, Sicherheit und Immunogenität von ABP 938 8 mg im Vergleich zu EYLEA® HD (Aflibercept) bei Teilnehmern mit neovaskulärer altersbedingter Makuladegenerationhttps://ocubrief.com/it/brief/nct07614776OcuBriefit2026-09-20T09:58:57.336ZStudio per valutare l'efficacia, la sicurezza e l'immunogenicità di ABP 938 8 mg in confronto a EYLEA® HD (aflibercept) in partecipanti con degenerazione maculare neovascolare legata all'etàhttps://ocubrief.com/en/brief/nct04591483OcuBriefen2026-09-20T09:58:57.336ZStargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4https://ocubrief.com/de/brief/nct04591483OcuBriefde2026-09-20T09:58:57.336ZStargardt-ähnliche Makuladystrophie (STDG3) sekundär zu Mutationen im ELOVL4-Genhttps://ocubrief.com/it/brief/nct04591483OcuBriefit2026-09-20T09:58:57.336ZDistrofia maculare simile a Stargardt (STDG3) secondaria a mutazioni nel gene ELOVL4https://ocubrief.com/en/brief/nct07824232OcuBriefen2026-09-20T09:58:57.336ZVisual Function and Exercise in Glaucoma Patientshttps://ocubrief.com/de/brief/nct07824232OcuBriefde2026-09-20T09:58:57.336ZVisuelle Funktion und körperliche Aktivität bei Glaukom-Patientenhttps://ocubrief.com/it/brief/nct07824232OcuBriefit2026-09-20T09:58:57.336ZFunzione visiva ed esercizio fisico in pazienti con glaucomahttps://ocubrief.com/en/brief/nct07734064OcuBriefen2026-09-20T09:58:57.336ZA Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditionshttps://ocubrief.com/de/brief/nct07734064OcuBriefde2026-09-20T09:58:57.336ZSicherheit einer einzelnen Augeninjektion von ASP2020 und möglicher Nutzen bei Sehverlust durch Stargardt-ähnliche Augenerkrankungenhttps://ocubrief.com/it/brief/nct07734064OcuBriefit2026-09-20T09:58:57.336ZSicurezza di una singola iniezione oculare di ASP2020 e valutazione del possibile beneficio nella perdita visiva associata a condizioni oculari di tipo Stargardthttps://ocubrief.com/en/brief/nct07821827OcuBriefen2026-09-20T09:58:57.336ZCombined Phacoemulsification-Goniotomy in Primary Open-Angle and Primary Angle-Closure Glaucomahttps://ocubrief.com/de/brief/nct07821827OcuBriefde2026-09-20T09:58:57.336ZKombinierte Phakoemulsifikation-Goniotomie bei primärem Offenwinkel- und primärem Engwinkelglaukomhttps://ocubrief.com/it/brief/nct07821827OcuBriefit2026-09-20T09:58:57.336ZFacoemulsificazione e goniotomia combinate nel glaucoma primario ad angolo aperto e nel glaucoma primario da chiusura d’angolohttps://ocubrief.com/en/brief/nct06879301OcuBriefen2026-09-20T09:58:57.336ZEffectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema, Retinal Vein Occlusion and Myopic Choroidal Neovascularisation Patientshttps://ocubrief.com/de/brief/nct06879301OcuBriefde2026-09-20T09:58:57.336ZWirksamkeit der intravitrealen Injektion von Aflibercept 8 mg bei Patienten mit resistentem diabetischem Makulaödem, retinaler Venenokklusion und myoper Choroidalneovaskularisationhttps://ocubrief.com/it/brief/nct06879301OcuBriefit2026-09-20T09:58:57.336ZEfficacia dell'iniezione intravitreale di aflibercept 8 mg in pazienti con edema maculare diabetico resistente, occlusione venosa retinica e neovascolarizzazione coroidea miopicahttps://ocubrief.com/en/brief/nct03135327OcuBriefen2026-09-20T09:58:57.336ZClinical Applications of Advanced Ophthalmic Imaginghttps://ocubrief.com/de/brief/nct03135327OcuBriefde2026-09-20T09:58:57.336ZKlinische Anwendungen der fortgeschrittenen ophthalmischen Bildgebunghttps://ocubrief.com/it/brief/nct03135327OcuBriefit2026-09-20T09:58:57.336ZApplicazioni cliniche dell'imaging oculistico avanzatohttps://ocubrief.com/en/brief/nct05839041OcuBriefen2026-09-20T09:58:57.336ZA Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)https://ocubrief.com/de/brief/nct05839041OcuBriefde2026-09-20T09:58:57.336ZStudie mit mehrfacher Dosis von AVD-104 bei geografischer Atrophie (GA) sekundär zur altersabhängigen Makuladegeneration (AMD)https://ocubrief.com/it/brief/nct05839041OcuBriefit2026-09-20T09:58:57.336ZStudio con dose multipla di AVD-104 per l'atrofia geografica (GA) secondaria alla degenerazione maculare legata all'età (AMD)https://ocubrief.com/en/brief/nct07270133OcuBriefen2026-09-20T09:58:57.336ZLongitudinal Natural History Study of Retinal Function in Eyes of Patients With Diabeteshttps://ocubrief.com/de/brief/nct07270133OcuBriefde2026-09-20T09:58:57.336ZLängsschnittstudie zur natürlichen Geschichte der retinalen Funktion bei Patienten mit Diabeteshttps://ocubrief.com/it/brief/nct07270133OcuBriefit2026-09-20T09:58:57.336ZStudio longitudinale sulla storia naturale della funzione retinica nei pazienti con diabetehttps://ocubrief.com/en/brief/nct02959242OcuBriefen2026-09-20T09:58:57.336ZDresden Glaucoma and Treatment Study (DGTS)https://ocubrief.com/de/brief/nct02959242OcuBriefde2026-09-20T09:58:57.336ZDresdner Glaukom- und Behandlungsstudie (DGTS)https://ocubrief.com/it/brief/nct02959242OcuBriefit2026-09-20T09:58:57.336ZStudio di Dresda sul glaucoma e sul trattamento (DGTS)https://ocubrief.com/en/brief/nct07811726OcuBriefen2026-09-20T09:58:57.336ZA Phase 2 Study of NT-101 Topical in Patients With Wet AMDhttps://ocubrief.com/de/brief/nct07811726OcuBriefde2026-09-20T09:58:57.336ZPhase-2-Studie zu topischem NT-101 bei neovaskulärer AMDhttps://ocubrief.com/it/brief/nct07811726OcuBriefit2026-09-20T09:58:57.336ZStudio di fase 2 di NT-101 topico in pazienti con AMD neovascolarehttps://ocubrief.com/en/brief/nct06319872OcuBriefen2026-09-20T09:58:57.336ZThe Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degenerationhttps://ocubrief.com/de/brief/nct06319872OcuBriefde2026-09-20T09:58:57.336ZDie Auswirkungen von Disulfiram (Antabuse®) auf die Sehschärfe bei Patienten mit retinaler Degenerationhttps://ocubrief.com/it/brief/nct06319872OcuBriefit2026-09-20T09:58:57.336ZGli effetti del disulfiram (Antabuse®) sull'acuità visiva in pazienti con degenerazione retinicahttps://ocubrief.com/en/brief/nct05300724OcuBriefen2026-09-20T09:58:57.336ZAn Observational Study of the Progression of Intermediate Age-Related Macular Degenerationhttps://ocubrief.com/de/brief/nct05300724OcuBriefde2026-09-20T09:58:57.336ZEine Beobachtungsstudie zur Progression der altersbedingten Makuladegeneration im mittleren Stadiumhttps://ocubrief.com/it/brief/nct05300724OcuBriefit2026-09-20T09:58:57.336ZUno studio osservazionale sulla progressione della degenerazione maculare legata all'età in stadio intermediohttps://ocubrief.com/en/brief/nct01432847OcuBriefen2026-09-20T09:58:57.336ZCell Collection to Study Eye Diseaseshttps://ocubrief.com/de/brief/nct01432847OcuBriefde2026-09-20T09:58:57.336ZZellensammlung zur Erforschung von Augenerkrankungenhttps://ocubrief.com/it/brief/nct01432847OcuBriefit2026-09-20T09:58:57.336ZRaccolta di cellule per lo studio di malattie ocularihttps://ocubrief.com/en/brief/nct06321302OcuBriefen2026-09-20T09:58:57.336ZA Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathyhttps://ocubrief.com/de/brief/nct06321302OcuBriefde2026-09-20T09:58:57.336ZEine Studie zur Überprüfung, ob BI 764524 bei Patienten mit diabetischer Retinopathie hilfthttps://ocubrief.com/it/brief/nct06321302OcuBriefit2026-09-20T09:58:57.336ZUno studio per verificare se il farmaco BI 764524 aiuta le persone con retinopatia diabeticahttps://ocubrief.com/en/brief/nct07249216OcuBriefen2026-09-20T09:58:57.336ZIdentification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Settinghttps://ocubrief.com/de/brief/nct07249216OcuBriefde2026-09-20T09:58:57.336ZIdentifizierung molekularer Signale im Glaskörper in Zusammenhang mit einer suboptimalen Reaktion auf die Hemmung des vaskulären endothelialen Wachstumsfaktors (VEGF) bei neovaskulärer altersbedingter Makuladegeneration (nAMD) im Rahmen einer klinischen Studiehttps://ocubrief.com/it/brief/nct07249216OcuBriefit2026-09-20T09:58:57.336ZIdentificazione di segnali molecolari nell'umore vitreo associati a una risposta subottimale all'inibizione del fattore di crescita endoteliale vascolare (VEGF) nella degenerazione maculare legata all'età neovascolare (nAMD) in un contesto di studio clinicohttps://ocubrief.com/en/brief/siglec-geographic-atrophy-registryOcuBriefen2026-09-20T09:58:57.336ZGeographic atrophy: the SIGLEC record is updatedhttps://ocubrief.com/de/brief/siglec-geographic-atrophy-registryOcuBriefde2026-09-20T09:58:57.336ZGeographische Atrophie: SIGLEC-Registereintrag aktualisierthttps://ocubrief.com/it/brief/siglec-geographic-atrophy-registryOcuBriefit2026-09-20T09:58:57.336ZAtrofia geografica: aggiornato il registro SIGLEChttps://ocubrief.com/en/brief/nct07821203OcuBriefen2026-09-20T09:58:57.336ZSubincisional Pockets for Sealing Clear Corneal Incisions in Cataract Surgeryhttps://ocubrief.com/de/brief/nct07821203OcuBriefde2026-09-20T09:58:57.336ZSubinzisionale Taschen zur Abdichtung klarer Hornhautinzisionen bei Kataraktoperationenhttps://ocubrief.com/it/brief/nct07821203OcuBriefit2026-09-20T09:58:57.336ZTasche subincisionali per sigillare le incisioni in cornea chiara nella chirurgia della catarattahttps://ocubrief.com/en/brief/nct03016156OcuBriefen2026-09-20T09:58:57.336ZDetermination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastomahttps://ocubrief.com/de/brief/nct03016156OcuBriefde2026-09-20T09:58:57.336ZBestimmung der Sensitivität und Spezifität einer Smartphone-Anwendung zur Erkennung von Retinoblastomhttps://ocubrief.com/it/brief/nct03016156OcuBriefit2026-09-20T09:58:57.336ZDeterminazione della sensibilità e della specificità di un'applicazione per smartphone per rilevare il retinoblastomahttps://ocubrief.com/en/brief/nct05626114OcuBriefen2026-09-20T09:58:57.336ZA Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251https://ocubrief.com/de/brief/nct05626114OcuBriefde2026-09-20T09:58:57.336ZEine Studie zur Optimierung der subretinalen chirurgischen Applikation und zur Bewertung der Sicherheit und Aktivität von Opregen bei Teilnehmern mit geografischer Atrophie infolge altersbedingter Makuladegeneration (GAlette); Adaptive-Optik-(AO)-Retina-Bildgebung-Substudie in Verbindung mit der Studie GR44251https://ocubrief.com/it/brief/nct05626114OcuBriefit2026-09-20T09:58:57.336ZUno studio per ottimizzare la somministrazione chirurgica sottoretinica e valutare la sicurezza e l'attività di Opregen in partecipanti con atrofia geografica secondaria a degenerazione maculare legata all'età (GAlette); sottostudio di imaging retinico con ottica adattiva (AO) in associazione con lo studio GR44251https://ocubrief.com/en/brief/nct07245082OcuBriefen2026-09-20T09:58:57.336ZPatients With Type 2 Diabeteshttps://ocubrief.com/de/brief/nct07245082OcuBriefde2026-09-20T09:58:57.336ZPatienten mit Typ-2-Diabeteshttps://ocubrief.com/it/brief/nct07245082OcuBriefit2026-09-20T09:58:57.336ZPazienti con diabete di tipo 2https://ocubrief.com/en/brief/nct06822738OcuBriefen2026-09-20T09:58:57.336ZA Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucomahttps://ocubrief.com/de/brief/nct06822738OcuBriefde2026-09-20T09:58:57.336ZBewertung von unerwünschten Ereignissen und Wirksamkeit der Gel-Stent-(XEN63)-Implantation mittels Ab-Interno- und Ab-Externo-Ansatz bei erwachsenen Teilnehmern mit Glaukomhttps://ocubrief.com/it/brief/nct06822738OcuBriefit2026-09-20T09:58:57.336ZValutazione degli eventi avversi e dell'efficacia dell'impianto di stent in gel (XEN63) utilizzando approcci ab interno e ab externo in partecipanti adulti con glaucomahttps://ocubrief.com/en/brief/nct07007065OcuBriefen2026-09-20T09:58:57.336ZStudy to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)https://ocubrief.com/de/brief/nct07007065OcuBriefde2026-09-20T09:58:57.336ZStudie zur Bewertung der Injektionsbelastung, unerwünschten Ereignissen, Veränderung der Krankheitsaktivität und langfristigen Erhaltung der Sehschärfe von Surabgene Lomparvovec bei erwachsenen Teilnehmern mit neovaskulärer altersbedingter Makuladegeneration (nAMD)https://ocubrief.com/it/brief/nct07007065OcuBriefit2026-09-20T09:58:57.336ZStudio per valutare il carico di iniezione, gli eventi avversi, il cambiamento dell'attività della malattia e la conservazione a lungo termine dell'acuità visiva di surabgene lomparvovec in partecipanti adulti con degenerazione maculare neovascolare legata all'età (nAMD)https://ocubrief.com/en/brief/nct03244072OcuBriefen2026-09-20T09:58:57.336ZSafety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgeryhttps://ocubrief.com/de/brief/nct03244072OcuBriefde2026-09-20T09:58:57.336ZSicherheit und Wirksamkeit von intrakameralem Zimoxin zur Prävention von Endophthalmitis nach Kataraktoperationhttps://ocubrief.com/it/brief/nct03244072OcuBriefit2026-09-20T09:58:57.336ZSicurezza ed efficacia di Zimoxin intracamerale per la prevenzione di endoftalmite dopo chirurgia della catarattahttps://ocubrief.com/en/brief/nct07820709OcuBriefen2026-09-20T09:58:57.336ZArtificial Intelligence for Staging Glaucoma Severity: A Comparison With an Eye Specialist Using Visual Field Testshttps://ocubrief.com/de/brief/nct07820709OcuBriefde2026-09-20T09:58:57.336ZKünstliche Intelligenz zur Einstufung der Glaukomschwere: Ein Vergleich mit einem Augenspezialisten unter Verwendung von Gesichtsfeldtestshttps://ocubrief.com/it/brief/nct07820709OcuBriefit2026-09-20T09:58:57.336ZIntelligenza artificiale per la stadiazione della gravità del glaucoma: un confronto con uno specialista oculistico utilizzando test del campo visivohttps://ocubrief.com/en/brief/nct07821450OcuBriefen2026-09-20T09:58:57.336ZBlepharoptosis After Repeated Intravitreal Anti-VEGF Injections: A Prospective Studyhttps://ocubrief.com/de/brief/nct07821450OcuBriefde2026-09-20T09:58:57.336ZBlepharoptose nach wiederholten intravitrealen anti-VEGF-Injektionen: Eine prospektive Studiehttps://ocubrief.com/it/brief/nct07821450OcuBriefit2026-09-20T09:58:57.336ZBlefaroptosi dopo iniezioni intravitreali ripetute di farmaci anti-VEGF: uno studio prospetticohttps://ocubrief.com/en/brief/nct07662096OcuBriefen2026-09-20T09:58:57.336ZA First-In-Human Study of ARO-033 in Adult Participantshttps://ocubrief.com/de/brief/nct07662096OcuBriefde2026-09-20T09:58:57.336ZEine First-in-Human-Studie von ARO-033 bei erwachsenen Teilnehmernhttps://ocubrief.com/it/brief/nct07662096OcuBriefit2026-09-20T09:58:57.336ZUno studio first-in-human di ARO-033 in partecipanti adultihttps://ocubrief.com/en/brief/nct07819253OcuBriefen2026-09-20T09:58:57.336ZLaser Photocoagulation and Ranibizumab Treatment in Proliferative Diabetic Retinopathyhttps://ocubrief.com/de/brief/nct07819253OcuBriefde2026-09-20T09:58:57.336ZLaser-Photokoagulation und Ranibizumab-Behandlung bei proliferativer diabetischer Retinopathiehttps://ocubrief.com/it/brief/nct07819253OcuBriefit2026-09-20T09:58:57.336ZFotocoagulazione laser e trattamento con ranibizumab nella retinopatia diabetica proliferativahttps://ocubrief.com/en/brief/nct01969786OcuBriefen2026-09-20T09:58:57.336ZVillage Integrated Eye Workers Trialhttps://ocubrief.com/de/brief/nct01969786OcuBriefde2026-09-20T09:58:57.336ZStudie zur integrierten augenmedizinischen Versorgung durch Gesundheitsmitarbeiter in Dörfernhttps://ocubrief.com/it/brief/nct01969786OcuBriefit2026-09-20T09:58:57.336ZStudio sugli operatori di assistenza oculistica integrata nei villaggihttps://ocubrief.com/en/brief/nct07354477OcuBriefen2026-09-20T09:58:57.336ZSingle-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilationhttps://ocubrief.com/de/brief/nct07354477OcuBriefde2026-09-20T09:58:57.336ZMonozentrische Pilotstudie zur Wirkung der QLS-111-Augentropfenlösung auf die posteriore Perfusion und Gefäßerweiterunghttps://ocubrief.com/it/brief/nct07354477OcuBriefit2026-09-20T09:58:57.336ZStudio pilota monocentrico sull’effetto della soluzione oftalmica QLS-111 sulla perfusione posteriore e sulla dilatazione vascolarehttps://ocubrief.com/en/brief/nct07588100OcuBriefen2026-09-20T09:58:57.336ZA Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathyhttps://ocubrief.com/de/brief/nct07588100OcuBriefde2026-09-20T09:58:57.336ZStudie zur Untersuchung der Sicherheit, Verträglichkeit und Pharmakokinetik von RO7663498 nach intravitrealer Verabreichung bei Teilnehmern mit diabetischer Retinopathiehttps://ocubrief.com/it/brief/nct07588100OcuBriefit2026-09-20T09:58:57.336ZStudio per indagare la sicurezza, la tollerabilità e la farmacocinetica di RO7663498 dopo somministrazione intravitreale in partecipanti con retinopatia diabeticahttps://ocubrief.com/en/brief/nct07817615OcuBriefen2026-09-20T09:58:57.336ZA Phase I Study of GenSci148 Intravitreal Injection for Neovascular Age-related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusionhttps://ocubrief.com/de/brief/nct07817615OcuBriefde2026-09-20T09:58:57.336ZPhase-I-Studie zur GenSci148-Intravitrealinjektion bei neovaskulärer altersbedingter Makuladegeneration, diabetischem Makulaödem und retinaler Venenokklusionhttps://ocubrief.com/it/brief/nct07817615OcuBriefit2026-09-20T09:58:57.336ZStudio di fase I di GenSci148 per iniezione intravitreale per degenerazione maculare neovascolare legata all'età, edema maculare diabetico e occlusione venosa retinicahttps://ocubrief.com/en/brief/nct07816887OcuBriefen2026-09-20T09:58:57.336ZEvaluation of Vitreous Modifications After Cataract Surgeryhttps://ocubrief.com/de/brief/nct07816887OcuBriefde2026-09-20T09:58:57.336ZBewertung von Veränderungen des Glaskörpers nach Kataraktoperationhttps://ocubrief.com/it/brief/nct07816887OcuBriefit2026-09-20T09:58:57.336ZValutazione delle modifiche del vitreo dopo chirurgia della catarattahttps://ocubrief.com/en/brief/nct07816692OcuBriefen2026-09-20T09:58:57.336ZiDose TR Administration in an Office-Based Surgery Settinghttps://ocubrief.com/de/brief/nct07816692OcuBriefde2026-09-20T09:58:57.336ZIDose-TR-Anwendung im Rahmen praxisbasierter Chirurgiehttps://ocubrief.com/it/brief/nct07816692OcuBriefit2026-09-20T09:58:57.336ZSomministrazione di iDose TR in un contesto chirurgico ambulatorialehttps://ocubrief.com/en/brief/nct06635148OcuBriefen2026-09-20T09:58:57.336ZA Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)https://ocubrief.com/de/brief/nct06635148OcuBriefde2026-09-20T09:58:57.336ZLangzeit-Verlängerung der Ausgangsstudien zu JNJ-81201887 (AAVCAGsCD59) bei geografischer Atrophie (GA) infolge altersbedingter Makuladegeneration (AMD)https://ocubrief.com/it/brief/nct06635148OcuBriefit2026-09-20T09:58:57.336ZEstensione a lungo termine degli studi originari di JNJ-81201887 (AAVCAGsCD59) in partecipanti con atrofia geografica (GA) secondaria a degenerazione maculare legata all’età (AMD)https://ocubrief.com/en/brief/nct04567303OcuBriefen2026-09-20T09:58:57.336ZStudy of Zifibancimig in Participants With Neovascular Age-related Macular Degenerationhttps://ocubrief.com/de/brief/nct04567303OcuBriefde2026-09-20T09:58:57.336ZStudie zu Zifibancimig bei Teilnehmern mit neovaskulärer altersbedingter Makuladegenerationhttps://ocubrief.com/it/brief/nct04567303OcuBriefit2026-09-20T09:58:57.336ZStudio di zifibancimig in partecipanti con degenerazione maculare neovascolare legata all'etàhttps://ocubrief.com/en/brief/nct06925477OcuBriefen2026-09-20T09:58:57.336ZDirect vs. Conventional SLT in Open-Angle Glaucoma: A RCThttps://ocubrief.com/de/brief/nct06925477OcuBriefde2026-09-20T09:58:57.336ZDirektes vs. konventionelles SLT bei Offenwinkelglaukom: Eine randomisierte kontrollierte Studiehttps://ocubrief.com/it/brief/nct06925477OcuBriefit2026-09-20T09:58:57.336ZSLT diretto vs convenzionale nel glaucoma ad angolo aperto: uno studio randomizzato controllatohttps://ocubrief.com/en/brief/nct05235321OcuBriefen2026-09-20T09:58:57.336ZAutomated Applanation Tonometryhttps://ocubrief.com/de/brief/nct05235321OcuBriefde2026-09-20T09:58:57.336ZAutomatisierte Applanationstonometriehttps://ocubrief.com/it/brief/nct05235321OcuBriefit2026-09-20T09:58:57.336ZTonometria ad applanazione automatizzatahttps://ocubrief.com/en/brief/nct07816289OcuBriefen2026-09-20T09:58:57.336ZPhase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05)https://ocubrief.com/de/brief/nct07816289OcuBriefde2026-09-20T09:58:57.336ZPhase-3-Studie zu intravitrealem OLN324 bei Erwachsenen mit neovaskulärer (feuchter) altersbedingter Makuladegeneration (nAMD) (OLN324-CP-05)https://ocubrief.com/it/brief/nct07816289OcuBriefit2026-09-20T09:58:57.336ZStudio di fase 3 su OLN324 intravitreale in adulti con degenerazione maculare neovascolare (umida) legata all'età (nAMD) (OLN324-CP-05)https://ocubrief.com/en/brief/nct06213038OcuBriefen2026-09-20T09:58:57.336ZA Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macular Degeneration (nAMD)https://ocubrief.com/de/brief/nct06213038OcuBriefde2026-09-20T09:58:57.336ZKlinische Studie zur Bewertung der Sicherheit und Wirksamkeit von SKG0106 bei Patienten mit neovaskulärer altersbedingter Makuladegeneration (nAMD)https://ocubrief.com/it/brief/nct06213038OcuBriefit2026-09-20T09:58:57.336ZStudio clinico per valutare la sicurezza e l'efficacia di SKG0106 in pazienti con degenerazione maculare neovascolare legata all'età (nAMD)https://ocubrief.com/en/brief/nct06970665OcuBriefen2026-09-20T09:58:57.336ZA Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degenerationhttps://ocubrief.com/de/brief/nct06970665OcuBriefde2026-09-20T09:58:57.336ZSicherheit von ASP3021-Augeninjektionen und möglicher Nutzen bei Sehverlust durch altersbedingte Makuladegeneration in Japanhttps://ocubrief.com/it/brief/nct06970665OcuBriefit2026-09-20T09:58:57.336ZSicurezza delle iniezioni oculari di ASP3021 e possibile beneficio per le persone con perdita visiva da degenerazione maculare legata all’età in Giapponehttps://ocubrief.com/en/brief/nct07770685OcuBriefen2026-09-20T09:58:57.336ZA Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damagehttps://ocubrief.com/de/brief/nct07770685OcuBriefde2026-09-20T09:58:57.336ZSicherheit von ASP2767 und möglicher Nutzen bei glaukomatöser Schädigung des Sehnervshttps://ocubrief.com/it/brief/nct07770685OcuBriefit2026-09-20T09:58:57.336ZSicurezza di ASP2767 e possibile beneficio nel danno del nervo ottico da glaucomahttps://ocubrief.com/en/brief/nct04663750OcuBriefen2026-09-20T09:58:57.336ZVitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).https://ocubrief.com/de/brief/nct04663750OcuBriefde2026-09-20T09:58:57.336ZVitrektomie, subretinaler Gewebeplasminogenaktivator (TPA) und intravitreales Gas bei submakulärer Blutung infolge exsudativer altersbedingter Makuladegeneration (TIGER)https://ocubrief.com/it/brief/nct04663750OcuBriefit2026-09-20T09:58:57.336ZVitrectomia, attivatore del plasminogeno tessutale subretinico (TPA) e gas intravitreale per emorragie submaculari secondarie alla degenerazione maculare esudativa (umida) legata all'età (TIGER)https://ocubrief.com/en/brief/nct06164743OcuBriefen2026-09-20T09:58:57.336ZPhase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgeryhttps://ocubrief.com/de/brief/nct06164743OcuBriefde2026-09-20T09:58:57.336ZPhase 2: VVN461-Augenlösung für postoperative okuläre Entzündung nach Kataraktoperationhttps://ocubrief.com/it/brief/nct06164743OcuBriefit2026-09-20T09:58:57.336ZFase 2: soluzione oculare VVN461 per infiammazione oculare postoperatoria dopo chirurgia della catarattahttps://ocubrief.com/en/brief/nct07816315OcuBriefen2026-09-20T09:58:57.336ZPhase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04)https://ocubrief.com/de/brief/nct07816315OcuBriefde2026-09-20T09:58:57.336ZPhase-3-Studie zu intravitrealem OLN324 bei Erwachsenen mit neovaskulärer (feuchter) altersbedingter Makuladegeneration (nAMD) (OLN324-CP-04)https://ocubrief.com/it/brief/nct07816315OcuBriefit2026-09-20T09:58:57.336ZStudio di fase 3 su OLN324 intravitreale in adulti con degenerazione maculare neovascolare (umida) legata all'età (nAMD) (OLN324-CP-04)https://ocubrief.com/en/brief/nct07808333OcuBriefen2026-09-20T09:58:57.336ZNicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial)https://ocubrief.com/de/brief/nct07808333OcuBriefde2026-09-20T09:58:57.336ZNikotinamid zum Schutz der Retina bei primärem Offenwinkelglaukom (NADIR-Studie)https://ocubrief.com/it/brief/nct07808333OcuBriefit2026-09-20T09:58:57.336ZNicotinamide per la protezione della retina nel glaucoma primario ad angolo aperto (studio NADIR)https://ocubrief.com/en/brief/nct07099079OcuBriefen2026-09-20T09:58:57.336ZPost-Market Clinical Follow-Up Study on the Rotational Stability of an Intraocular Lens After Cataract Surgeryhttps://ocubrief.com/de/brief/nct07099079OcuBriefde2026-09-20T09:58:57.336ZKlinische Nachbeobachtungsstudie nach Markteinführung zur Rotationsstabilität einer Intraokularlinse nach Kataraktoperationhttps://ocubrief.com/it/brief/nct07099079OcuBriefit2026-09-20T09:58:57.336ZStudio di follow-up clinico post-commercializzazione sulla stabilità rotazionale di una lente intraoculare dopo chirurgia della catarattahttps://ocubrief.com/en/brief/nct07798375OcuBriefen2026-09-20T09:58:57.336ZA Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degenerationhttps://ocubrief.com/de/brief/nct07798375OcuBriefde2026-09-20T09:58:57.336ZStudie zur Bewertung der Wirksamkeit und Sicherheit von VIS-101 bei Teilnehmern mit neovaskulärer altersbedingter Makuladegenerationhttps://ocubrief.com/it/brief/nct07798375OcuBriefit2026-09-20T09:58:57.336ZStudio per valutare l'efficacia e la sicurezza di VIS-101 in partecipanti con degenerazione maculare neovascolare legata all'etàhttps://ocubrief.com/en/brief/nct07394257OcuBriefen2026-09-20T09:58:57.336ZIntrastromal Moxifloxacin as an Adjunctive Therapy in Recalcitrant Bacterial Keratitishttps://ocubrief.com/de/brief/nct07394257OcuBriefde2026-09-20T09:58:57.336ZIntrastromales Moxifloxacin als Zusatztherapie bei therapieresistenter bakterieller Keratitishttps://ocubrief.com/it/brief/nct07394257OcuBriefit2026-09-20T09:58:57.336ZMoxifloxacina intrastromale come terapia aggiuntiva nella cheratite batterica refrattariahttps://ocubrief.com/en/brief/nct07812090OcuBriefen2026-09-20T09:58:57.336ZA Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edemahttps://ocubrief.com/de/brief/nct07812090OcuBriefde2026-09-20T09:58:57.336ZRandomisierte Phase-2-Studie zu oralem BGE-102 bei zentrumsbeteiligtem diabetischem Makulaödemhttps://ocubrief.com/it/brief/nct07812090OcuBriefit2026-09-20T09:58:57.336ZStudio randomizzato di fase 2 su BGE-102 orale in partecipanti con edema maculare diabetico a coinvolgimento centralehttps://ocubrief.com/en/brief/nct07237555OcuBriefen2026-09-20T09:58:57.336ZCVL Risk After Severe Glaucoma Surgeryhttps://ocubrief.com/de/brief/nct07237555OcuBriefde2026-09-20T09:58:57.336ZCVL-Risiko nach Operation bei schwerem Glaukomhttps://ocubrief.com/it/brief/nct07237555OcuBriefit2026-09-20T09:58:57.336ZRischio di CVL dopo chirurgia per glaucoma gravehttps://ocubrief.com/en/brief/nct07762053OcuBriefen2026-09-20T09:58:57.336ZClinical Investigation of Eye C Better's Photobionic Intraocular Pressure Biomonitor Tonometerhttps://ocubrief.com/de/brief/nct07762053OcuBriefde2026-09-20T09:58:57.336ZKlinische Untersuchung des photobionischen Augeninnendruck-Biomonitors und Tonometers von Eye C Betterhttps://ocubrief.com/it/brief/nct07762053OcuBriefit2026-09-20T09:58:57.336ZIndagine clinica sul tonometro con biomonitoraggio fotobionico della pressione intraoculare di Eye C Betterhttps://ocubrief.com/en/brief/nct06659445OcuBriefen2026-09-20T09:58:57.336ZStudy to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMDhttps://ocubrief.com/de/brief/nct06659445OcuBriefde2026-09-20T09:58:57.336ZStudie zur Bewertung der Wirksamkeit und Sicherheit von ONL1204 bei Patienten mit GA assoziiert mit AMDhttps://ocubrief.com/it/brief/nct06659445OcuBriefit2026-09-20T09:58:57.336ZStudio per valutare l'efficacia e la sicurezza di ONL1204 in pazienti con atrofia geografica associata alla degenerazione maculare legata all'etàhttps://ocubrief.com/en/brief/nct05984927OcuBriefen2026-09-20T09:58:57.336ZNG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degenerationhttps://ocubrief.com/de/brief/nct05984927OcuBriefde2026-09-20T09:58:57.336ZNG101 AAV-Gentherapie bei Probanden mit feuchter altersbedingter Makuladegenerationhttps://ocubrief.com/it/brief/nct05984927OcuBriefit2026-09-20T09:58:57.336ZTerapia genica NG101 AAV in soggetti con degenerazione maculare umida legata all'etàhttps://ocubrief.com/en/brief/nct07441642OcuBriefen2026-09-20T09:58:57.336ZA Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degenerationhttps://ocubrief.com/de/brief/nct07441642OcuBriefde2026-09-20T09:58:57.336ZStudie zur Untersuchung der Wirksamkeit und Sicherheit von FWY003 im Vergleich zu Placebo bei Teilnehmern mit geografischer Atrophie infolge altersbedingter Makuladegenerationhttps://ocubrief.com/it/brief/nct07441642OcuBriefit2026-09-20T09:58:57.336ZStudio per valutare l'efficacia e la sicurezza di FWY003 in confronto al placebo in partecipanti con atrofia geografica secondaria a degenerazione maculare legata all'etàhttps://ocubrief.com/en/brief/nct07804277OcuBriefen2026-09-20T09:58:57.336ZComparative Study of the Tomey FT-1000, and Goldmann Applanation Tonometer (GAT)https://ocubrief.com/de/brief/nct07804277OcuBriefde2026-09-20T09:58:57.336ZVergleichsstudie zwischen Tomey FT-1000 und Goldmann-Applanationstonometer (GAT)https://ocubrief.com/it/brief/nct07804277OcuBriefit2026-09-20T09:58:57.336ZStudio comparativo tra Tomey FT-1000 e tonometro ad applanazione di Goldmann (GAT)https://ocubrief.com/en/brief/nct06825702OcuBriefen2026-09-20T09:58:57.336ZSafety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edemahttps://ocubrief.com/de/brief/nct06825702OcuBriefde2026-09-20T09:58:57.336ZSicherheit, Verträglichkeit und Wirksamkeit von intravitrealem KIO-104 bei Patienten mit Makulaödemhttps://ocubrief.com/it/brief/nct06825702OcuBriefit2026-09-20T09:58:57.336ZSicurezza, tollerabilità ed efficacia di KIO-104 intravitreale in pazienti con edema macularehttps://ocubrief.com/en/brief/nct07809022OcuBriefen2026-09-20T09:58:57.336ZTemporary Tear Duct Filling With Hyaluronic Acid Gel and Assessment of Dry Eye Disease (DED) After Bilateral Cataract Surgeryhttps://ocubrief.com/de/brief/nct07809022OcuBriefde2026-09-20T09:58:57.336ZTemporäre Tränengangfüllung mit Hyaluronsäure-Gel und Bewertung der Erkrankung des trockenen Auges (DED) nach bilateraler Kataraktoperationhttps://ocubrief.com/it/brief/nct07809022OcuBriefit2026-09-20T09:58:57.336ZRiempimento temporaneo del dotto lacrimale con gel di acido ialuronico e valutazione della malattia dell'occhio secco (DED) dopo chirurgia della cataratta bilateralehttps://ocubrief.com/en/brief/nct06960629OcuBriefen2026-09-20T09:58:57.336ZThe Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK)https://ocubrief.com/de/brief/nct06960629OcuBriefde2026-09-20T09:58:57.336ZEffekt von ROCK-Hemmern auf die Kornea von Patienten mit Glaukom und pseudophakischer bullöser Keratopathie (PBK)https://ocubrief.com/it/brief/nct06960629OcuBriefit2026-09-20T09:58:57.336ZEffetto degli inibitori di ROCK sulla cornea di pazienti con glaucoma e cheratopatia bullosa pseudofachica (PBK)https://ocubrief.com/en/brief/nct01957267OcuBriefen2026-09-20T09:58:57.336ZFunctional and Structural Imaging for Glaucomahttps://ocubrief.com/de/brief/nct01957267OcuBriefde2026-09-20T09:58:57.336ZFunktionelle und strukturelle Bildgebung bei Glaukomhttps://ocubrief.com/it/brief/nct01957267OcuBriefit2026-09-20T09:58:57.336ZImaging funzionale e strutturale nel glaucomahttps://ocubrief.com/en/brief/nct05310422OcuBriefen2026-09-20T09:58:57.336ZSafety Study of Tivanisiran to Treat Dry Eyehttps://ocubrief.com/de/brief/nct05310422OcuBriefde2026-09-20T09:58:57.336ZSicherheitsstudie von Tivanisiran zur Behandlung der Erkrankung des trockenen Augeshttps://ocubrief.com/it/brief/nct05310422OcuBriefit2026-09-20T09:58:57.336ZStudio di sicurezza di Tivanisiran per il trattamento della malattia dell'occhio seccohttps://ocubrief.com/en/brief/nct03811561OcuBriefen2026-09-20T09:58:57.336ZA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabeteshttps://ocubrief.com/de/brief/nct03811561OcuBriefde2026-09-20T09:58:57.336ZForschungsstudie zur Untersuchung, wie Semaglutid im Vergleich zu Placebo die diabetische Augenerkrankung bei Menschen mit Typ-2-Diabetes beeinflussthttps://ocubrief.com/it/brief/nct03811561OcuBriefit2026-09-20T09:58:57.336ZStudio di ricerca per valutare come semaglutide in confronto al placebo influisce sulla malattia oculare diabetica in persone con diabete di tipo 2https://ocubrief.com/en/brief/nct06969586OcuBriefen2026-09-20T09:58:57.336ZThe Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophyhttps://ocubrief.com/de/brief/nct06969586OcuBriefde2026-09-20T09:58:57.336ZDie Wirkung von topischen Rho-Kinase-Hemmern auf die Hornhäute von Patienten mit Fuchs-Endothel-Dystrophiehttps://ocubrief.com/it/brief/nct06969586OcuBriefit2026-09-20T09:58:57.336ZL'effetto degli inibitori della Rho-chinasi topici sulle cornee dei pazienti con distrofia corneale endoteliale di Fuchshttps://ocubrief.com/en/brief/nct07755748OcuBriefen2026-09-20T09:58:57.336ZGlaucoma Screening to Enhance At-Risk Californians' Health - Survey Response Incentiveshttps://ocubrief.com/de/brief/nct07755748OcuBriefde2026-09-20T09:58:57.336ZGlaukom-Screening zur Verbesserung der Gesundheit von gefährdeten Kaliforniern - Umfrageantwortanreizehttps://ocubrief.com/it/brief/nct07755748OcuBriefit2026-09-20T09:58:57.336ZScreening del glaucoma per migliorare la salute dei californiani a rischio - Incentivi per le risposte ai sondaggihttps://ocubrief.com/en/brief/nct01878045OcuBriefen2026-09-20T09:58:57.336ZMechanisms of Diabetic Kidney Disease in American Indianshttps://ocubrief.com/de/brief/nct01878045OcuBriefde2026-09-20T09:58:57.336ZMechanismen der diabetischen Nierenkrankheit bei amerikanischen Ureinwohnernhttps://ocubrief.com/it/brief/nct01878045OcuBriefit2026-09-20T09:58:57.336ZMeccanismi della malattia renale diabetica negli indiani americanihttps://ocubrief.com/en/brief/nct07807761OcuBriefen2026-09-20T09:58:57.336ZKatarak Surgery and Carehttps://ocubrief.com/de/brief/nct07807761OcuBriefde2026-09-20T09:58:57.336ZKatarakt-Chirurgie und -Versorgunghttps://ocubrief.com/it/brief/nct07807761OcuBriefit2026-09-20T09:58:57.336ZChirurgia e cura della catarattahttps://ocubrief.com/en/brief/nct03225131OcuBriefen2026-09-20T09:58:57.336ZDark Adaptation in Participants With Age-Related Macular Degenerationhttps://ocubrief.com/de/brief/nct03225131OcuBriefde2026-09-20T09:58:57.336ZDunkeladaptation bei Teilnehmern mit altersbedingter Makuladegenerationhttps://ocubrief.com/it/brief/nct03225131OcuBriefit2026-09-20T09:58:57.336ZAdattamento al buio in partecipanti con degenerazione maculare legata all'etàhttps://ocubrief.com/en/brief/nct01496625OcuBriefen2026-09-20T09:58:57.336ZNational Eye Institute Biorepository for Retinal Diseaseshttps://ocubrief.com/de/brief/nct01496625OcuBriefde2026-09-20T09:58:57.336ZNational Eye Institute Biorepository für retinale Erkrankungenhttps://ocubrief.com/it/brief/nct01496625OcuBriefit2026-09-20T09:58:57.336ZBiobanca del National Eye Institute per le malattie retinichehttps://ocubrief.com/en/brief/nct04697095OcuBriefen2026-09-20T09:58:57.336ZSurvival of Monocytes Collected From Patients With Atrophic AMD in Retinal Pigmented Epithelium Explantshttps://ocubrief.com/de/brief/nct04697095OcuBriefde2026-09-20T09:58:57.336ZÜberleben von Monozyten von Patienten mit atrophischer AMD in Explantaten des retinalen Pigmentepithelshttps://ocubrief.com/it/brief/nct04697095OcuBriefit2026-09-20T09:58:57.336ZSopravvivenza dei monociti raccolti da pazienti con AMD atrofica in espianti di epitelio pigmentato retinicohttps://ocubrief.com/en/brief/nct07481500OcuBriefen2026-09-20T09:58:57.336ZSpeculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: Pain, Procedure Time, Patient Satisfaction, and Safetyhttps://ocubrief.com/de/brief/nct07481500OcuBriefde2026-09-20T09:58:57.336ZIntravitreale Injektion ohne Lidsperrer mit Retraktion durch Wattestäbchen: Schmerzen, Eingriffsdauer, Patientenzufriedenheit und Sicherheithttps://ocubrief.com/it/brief/nct07481500OcuBriefit2026-09-20T09:58:57.336ZIniezione intravitreale senza blefarostato con retrazione mediante applicatore con punta di cotone: dolore, durata della procedura, soddisfazione del paziente e sicurezzahttps://ocubrief.com/en/brief/nct07807969OcuBriefen2026-09-20T09:58:57.336ZAn Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)https://ocubrief.com/de/brief/nct07807969OcuBriefde2026-09-20T09:58:57.336ZEine offene Verlängerungsstudie zur langfristigen Sicherheit von Vonaprument (ANX007) bei Teilnehmern mit trockener altersbedingter Makuladegeneration (AMD) mit geografischer Atrophie (GA)https://ocubrief.com/it/brief/nct07807969OcuBriefit2026-09-20T09:58:57.336ZUno studio di estensione aperto sulla sicurezza a lungo termine di Vonaprument (ANX007) in partecipanti con degenerazione maculare legata all'età secca (AMD) con atrofia geografica (GA)https://ocubrief.com/en/brief/nct07668193OcuBriefen2026-09-20T09:58:57.336ZGlaukomAI: Clinical Validation of an AI System for Early Glaucoma Screeninghttps://ocubrief.com/de/brief/nct07668193OcuBriefde2026-09-20T09:58:57.336ZGlaukomAI: Klinische Validierung eines KI-Systems für das frühe Glaukom-Screeninghttps://ocubrief.com/it/brief/nct07668193OcuBriefit2026-09-20T09:58:57.336ZGlaukomAI: convalida clinica di un sistema di intelligenza artificiale per lo screening precoce del glaucomahttps://ocubrief.com/en/brief/nct07452042OcuBriefen2026-09-20T09:58:57.336ZPostoperative Outcomes of a Toric AddOn Intraocular Lens After Keratoplasty and Cataract Surgeryhttps://ocubrief.com/de/brief/nct07452042OcuBriefde2026-09-20T09:58:57.336ZPostoperative Ergebnisse einer torischen AddOn-Intraokularlinse nach Keratoplastik und Kataraktchirurgiehttps://ocubrief.com/it/brief/nct07452042OcuBriefit2026-09-20T09:58:57.336ZRisultati postoperatori di una lente intraoculare torica AddOn dopo cheratoplastica e chirurgia della catarattahttps://ocubrief.com/en/brief/nct07205887OcuBriefen2026-09-20T09:58:57.336ZA Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVOhttps://ocubrief.com/de/brief/nct07205887OcuBriefde2026-09-20T09:58:57.336ZDosisverblindete Studie zu intravitrealem EYE103 bei NVAMD oder Makulaödem nach BRVOhttps://ocubrief.com/it/brief/nct07205887OcuBriefit2026-09-20T09:58:57.336ZStudio con mascheramento della dose di EYE103 intravitreale in partecipanti con NVAMD o edema maculare dopo BRVOhttps://ocubrief.com/en/brief/nct07554690OcuBriefen2026-09-20T09:58:57.336ZPhotobiomodulation Laser for Reticular Pseudodrusen in Age-Related Macular Degenerationhttps://ocubrief.com/de/brief/nct07554690OcuBriefde2026-09-20T09:58:57.336ZPhotobiomodulation-Laser für retikuläre Pseudodrusen bei altersabhängiger Makuladegenerationhttps://ocubrief.com/it/brief/nct07554690OcuBriefit2026-09-20T09:58:57.336ZLaser a fotobiomodulazione per pseudodrusen reticolari nella degenerazione maculare legata all'etàhttps://ocubrief.com/en/brief/nct07230184OcuBriefen2026-09-20T09:58:57.336ZTo Evaluate the Efficacy and Safety of Combination Therapy With B55R1 and B55R2 Compared to B55R1 Monotherapy in Patients With NPDRhttps://ocubrief.com/de/brief/nct07230184OcuBriefde2026-09-20T09:58:57.336ZBewertung der Wirksamkeit und Sicherheit einer Kombinationstherapie mit B55R1 und B55R2 im Vergleich zur Monotherapie mit B55R1 bei Patienten mit NPDRhttps://ocubrief.com/it/brief/nct07230184OcuBriefit2026-09-20T09:58:57.336ZValutazione dell'efficacia e della sicurezza della terapia combinata con B55R1 e B55R2 rispetto alla monoterapia con B55R1 in pazienti con NPDRhttps://ocubrief.com/en/brief/zeiss-escrs-2026-workflowOcuBriefen2026-09-20T09:58:57.336ZZEISS expands its cataract and digital workflow portfoliohttps://ocubrief.com/de/brief/zeiss-escrs-2026-workflowOcuBriefde2026-09-20T09:58:57.336ZZEISS erweitert das Katarakt- und Digitalportfoliohttps://ocubrief.com/it/brief/zeiss-escrs-2026-workflowOcuBriefit2026-09-20T09:58:57.336ZZEISS amplia il portfolio per cataratta e workflow digitalehttps://ocubrief.com/en/brief/mi-sight-pragmatic-protocolOcuBriefen2026-09-20T09:58:57.336ZMI-SIGHT 2: testing a technology-based screening pathwayhttps://ocubrief.com/de/brief/mi-sight-pragmatic-protocolOcuBriefde2026-09-20T09:58:57.336ZMI-SIGHT 2: technikgestütztes Screening im Praxistesthttps://ocubrief.com/it/brief/mi-sight-pragmatic-protocolOcuBriefit2026-09-20T09:58:57.336ZMI-SIGHT 2: un percorso di screening basato sulla tecnologiahttps://ocubrief.com/en/brief/eudamed-four-modulesOcuBriefen2026-09-20T09:58:57.336ZEUDAMED: four modules are now mandatoryhttps://ocubrief.com/de/brief/eudamed-four-modulesOcuBriefde2026-09-20T09:58:57.336ZEUDAMED: vier Module sind jetzt verpflichtendhttps://ocubrief.com/it/brief/eudamed-four-modulesOcuBriefit2026-09-20T09:58:57.336ZEUDAMED: quattro moduli sono ora obbligatori